Kineta, Inc. SEC Filings

Welcome to our dedicated page for Kineta SEC filings (Ticker: KA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

The SEC filings associated with Kineta, Inc. (historically Nasdaq: KA and later trading as KANT on OTC Pink) provide a detailed regulatory record of its activities as a clinical-stage biotechnology company and document its transition through a merger with TuHURA Biosciences, Inc. and subsequent deregistration. These filings are a key source for understanding Kineta’s immuno-oncology programs, corporate actions, and ultimate change in status.

For investors and researchers, periodic and current reports historically described Kineta’s focus on developing next-generation immunotherapies in oncology that address cancer immune resistance, including its lead VISTA blocking immunotherapy KVA12123 in the Phase 1/2 VISTA-101 trial for advanced solid tumors. Company disclosures summarized interim clinical data, safety and tolerability observations, and biomarker findings, as well as the impact of corporate restructuring and financing constraints on trial enrollment and operations.

Later filings center on strategic transactions and listing status. An 8-K dated June 24, 2025 reports that on June 23, 2025, Kineta stockholders approved the Agreement and Plan of Merger with TuHURA Biosciences, Hura Merger Sub I, Inc., and Hura Merger Sub II, LLC at a Special Meeting of Stockholders. The filing outlines the proposals presented to stockholders and the voting results, referencing a definitive joint proxy statement/prospectus that provides additional detail on the mergers.

A Form 15 (15-12G) filed on July 2, 2025 is particularly important for understanding Kineta’s current status. Submitted by Kineta, LLC as successor by merger to Kineta, Inc., it certifies the termination of registration of Kineta’s common stock under Section 12(g) of the Securities Exchange Act of 1934 and the suspension of reporting obligations under Sections 13 and 15(d). The explanatory note states that effective June 30, 2025, Merger Sub I merged with and into Kineta, Inc., and the surviving corporation then merged with and into Merger Sub II, which survived as a wholly owned subsidiary of TuHURA under the name Kineta, LLC. The Form 15 lists one holder of record as of the certification date.

Collectively, Kineta’s SEC filings trace the company’s path from a publicly traded clinical-stage immuno-oncology issuer, through restructuring and strategic review, to its combination with TuHURA and deregistration. On a filings platform, users can consult these documents to analyze the terms of the mergers, the rationale for corporate actions, and the regulatory steps that concluded with Kineta, LLC operating as a wholly owned subsidiary of TuHURA.